Harvard Bioscience (HBIO) 10-Q 8 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-33957
Entity Registrant Name	HARVARD BIOSCIENCE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		43,616,621
Entity Central Index Key	0001123494
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,569	$ 4,283
Accounts receivable, net	12,831	16,099
Inventories	25,990	24,716
Other current assets	3,401	3,940
Total current assets	46,791	49,038
Property, plant and equipment, net	5,221	3,981
Operating lease right-of-use assets	6,523	4,773
Goodwill	57,439	57,065
Intangible assets, net	12,341	16,036
Other long-term assets	2,924	6,473
Total assets	131,239	137,366
Current liabilities:
Current portion of long-term debt	3,606	5,859
Accounts payable	5,283	5,554
Contract liabilities	3,689	4,508
Other current liabilities	10,173	10,621
Total current liabilities	22,751	26,542
Long-term debt, net	34,252	30,704
Deferred tax liability	707	776
Operating lease liabilities	6,706	4,794
Other long-term liabilities	1,501	1,476
Total liabilities	65,917	64,292
Commitments and Contingencies
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,421,251 shares issued and outstanding at March 31, 2024; 43,394,509 shares issued and outstanding at December 31, 2023	436	434
Additional paid-in-capital	235,973	232,435
Accumulated deficit	(158,028)	(145,605)
Accumulated other comprehensive loss	(13,059)	(14,190)
Total stockholders' equity	65,322	73,074
Total liabilities and stockholders' equity	$ 131,239	$ 137,366

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized (in shares)	5,000,000	5,000,000
Common Stock, par value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized (in shares)	80,000,000	80,000,000
Common Stock, shares issued (in shares)	43,616,621	43,394,509
Common Stock, shares outstanding (in shares)	43,616,621	43,394,509

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 21,969	$ 25,363	$ 69,579	$ 84,097
Cost of revenues	9,205	10,636	28,824	34,351
Gross profit	12,765	14,727	40,755	49,746
Sales and marketing expenses	5,518	5,732	16,817	17,888
General and administrative expenses	5,041	5,807	16,690	17,494
Research and development expenses	2,567	2,760	8,078	8,614
Amortization of intangible assets	1,334	1,361	3,998	4,138
Other operating expenses	179	0	1,394	0
Total operating expenses	14,639	15,660	46,977	48,134
Operating (loss) income	(1,874)	(933)	(6,222)	1,612
Other income (expense):
Interest expense	(856)	(882)	(2,356)	(2,797)
Loss on pension settlement - Note 16	(1,243)	0	(1,243)	0
Gain (loss) on equity securities - Note 6	0	1,208	(1,593)	(373)
Other (expense) income, net	(518)	45	(841)	105
Total other (expense) income	(2,617)	371	(6,033)	(3,065)
Loss before income taxes	(4,491)	(562)	(12,255)	(1,453)
Income tax expense	311	677	168	144
Net (loss) income	$ (4,802)	$ (1,239)	$ (12,423)	$ (1,597)
(Loss) income per share:
Diluted (loss) income per share (in dollars per share)	$ (0.11)	$ (0.03)	$ (0.29)	$ (0.04)
Weighted-average common shares:
Diluted (in shares)	43,614	42,688	43,499	42,345

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net (loss) income	$ (4,802)	$ (1,239)	$ (12,423)	$ (1,597)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	1,596	(1,343)	685	(354)
Defined benefit pension plans	470	0	470	0
Derivative instruments qualifying as cash flow hedges, net of tax of $-0-	(257)	117	(24)	126
Other comprehensive (loss) income	1,809	(1,226)	1,131	(228)
Comprehensive (loss) income	$ (2,993)	$ (2,465)	$ (11,292)	$ (1,825)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022	42,082,000
Balance at Dec. 31, 2022	$ 454	$ 229,008	$ (142,190)	$ (15,052)	$ 72,220
Stock option exercises (in shares)	214,000
Stock option exercises	$ 3	506	0	0	509
Stock-based compensation	0	3,618	0	0	3,618
Net (loss) income	0	0	(1,597)	0	(1,597)
Other comprehensive income	$ 0	0	0	(228)	(228)
Balance (in shares) at Sep. 30, 2023	42,688,000
Balance at Sep. 30, 2023	$ 457	232,896	(143,787)	(15,280)	74,286
Stock purchase plan (in shares)	91,000
Stock purchase plan	$ 0	215	0	0	215
Vesting of restricted stock units (in shares)	413,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(112,000)
Shares withheld for taxes	$ 0	(451)	0	0	(451)
Net loss	$ 0	0	(1,597)	0	(1,597)
Balance (in shares) at Jun. 30, 2023	42,688,000
Balance at Jun. 30, 2023	$ 457	231,533	(142,548)	(14,054)	75,388
Stock-based compensation	0	1,363	0	0	1,363
Net (loss) income	0	0	(1,239)	0	(1,239)
Other comprehensive income	$ 0	0	0	(1,226)	(1,226)
Balance (in shares) at Sep. 30, 2023	42,688,000
Balance at Sep. 30, 2023	$ 457	232,896	(143,787)	(15,280)	74,286
Net loss	$ 0	0	(1,239)	0	(1,239)
Balance (in shares) at Dec. 31, 2023	43,395,000
Balance at Dec. 31, 2023	$ 434	232,435	(145,605)	(14,190)	$ 73,074
Stock option exercises (in shares)	14,000				13,586
Stock option exercises	$ 0	43	0	0	$ 43
Stock-based compensation	0	3,379	0	0	3,379
Net (loss) income	0	0	(12,423)	0	(12,423)
Other comprehensive income	$ 0	0	0	1,131	1,131
Balance (in shares) at Sep. 30, 2024	43,617,000
Balance at Sep. 30, 2024	$ 436	235,973	(158,028)	(13,059)	65,322
Stock purchase plan (in shares)	72,000
Stock purchase plan	$ 1	175	0	0	176
Vesting of restricted stock units (in shares)	150,000
Vesting of restricted stock units	$ 1	0	0	0	1
Shares withheld for taxes (in shares)	(14,000)
Shares withheld for taxes	$ 0	(59)	0	0	(59)
Net loss	$ 0	0	(12,423)	0	(12,423)
Balance (in shares) at Jun. 30, 2024	43,611,000
Balance at Jun. 30, 2024	$ 436	234,905	(153,226)	(14,868)	67,247
Stock option exercises (in shares)	6,000
Stock option exercises	$ 0	15	0	0	15
Stock-based compensation	0	1,053	0	0	1,053
Net (loss) income	0	0	(4,802)	0	(4,802)
Other comprehensive income	$ 0	0	0	1,809	1,809
Balance (in shares) at Sep. 30, 2024	43,617,000
Balance at Sep. 30, 2024	$ 436	235,973	(158,028)	(13,059)	65,322
Net loss	$ 0	$ 0	$ (4,802)	$ 0	$ (4,802)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net (loss) income	$ (12,423)	$ (1,597)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation	1,268	1,083
Amortization of intangible assets	4,129	4,138
Amortization of deferred financing costs	229	210
Stock-based compensation expense	3,379	3,618
Deferred income taxes and other	(361)	92
Loss on equity securities - Note 6	1,593	373
Loss on pension settlement - Note 16	1,243	0
Gain on sale of product line - Note 14	0	(403)
Changes in operating assets and liabilities:
Accounts receivable	3,303	1,751
Inventories	(2,416)	173
Other assets	873	50
Other assets	(873)	(50)
Accounts payable and other current liabilities	(283)	(298)
Contract liabilities	(819)	635
Net cash provided by operating activities	(285)	9,725
Cash flows from investing activities:
Additions to property, plant and equipment	(2,343)	(958)
Capitalized software development costs	(454)	(292)
Proceeds from sale of product line	0	512
Proceeds from sale of marketable equity securities	1,919	0
Net cash (used in) provided by investing activities	(878)	(738)
us-gaap_PaymentsOfDebtIssuanceCosts	161	0
Borrowing from revolving line of credit	8,800	3,500
Repayment of revolving line of credit	(2,550)	(8,450)
Repayment of term debt	(5,023)	(3,341)
Proceeds from exercise of stock options and employee stock purchase plan	219	724
Taxes paid related to net share settlement of equity awards	(59)	(451)
Net cash used in financing activities	1,226	(8,018)
Effect of exchange rate changes on cash	223	(137)
Decrease in cash and cash equivalents	286	832
Cash and cash equivalents at beginning of period	4,283	4,508
Cash and cash equivalents at end of period	4,569	5,340
Cash paid for interest	2,369	3,006
Cash paid for income taxes, net of refunds	$ 315	$ 168

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2023 consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2024, results of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the anticipated operating results for the full year ending December 31, 2024, or any future periods. The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2024. Liquidity Primarily due to a decline in revenues, the Company experienced a net cash outflow from operations during the nine months ended September 30, 2024. The Company has substantial debt and other financial obligations. Any failure to meet these obligations or maintain compliance with the debt covenants contained in its credit agreement could have a material adverse effect on its business, financial condition and results of operations. As of the date of this report, the Company is unable to make additional borrowings under its revolving credit facility due to net leverage ratio requirements set forth in the Company’s credit agreement and will be unable to make any such borrowings until it delivers to the lenders its financial statements for the year ending December 31, 2024 (see note 8). The Company continues to take actions intended to improve liquidity, including actions related to cost containment and inventory reduction. Based on its current operating plans, the Company expects that its available cash and cash generated from operations will be sufficient to finance operations and capital expenditures and service its debt for at least the next 12 months. The Company’s ongoing cash flows and ability to meet its debt covenants are dependent on its revenues and operating performance. If the Company is unable to successfully carry out its operating plans or increase its revenues, its ability to maintain compliance with its debt covenants could be adversely affected. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables, and defined benefit pension obligations. Estimates are also required to assess the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company assesses its previous estimates based upon currently available information. Actual results could differ materially from those estimates. Other Operating Expenses The components of other operating expenses for the three and nine months ended September 30, 2024 were as follows: Three Months Ended Nine Months Ended (in thousands) September 30, 2024 September 30, 2024 Restructuring expenses (see Note 15) $ 179 $ 575 Unclaimed property audits expense (see Note 13) - 347 Employee retention credit fees (see Note 5) - 472 Total other operating expenses $ 179 $ 1,394 Recently Issued Accounting Pronouncements Yet to Be Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax

Note 2 - Earnings (Loss) per Sh

Note 2 - Earnings (Loss) per Share	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	2. Earnings (Loss) per Share Basic earnings (loss) per share (EPS) is calculated by dividing net income (loss) by the number of weighted average shares of common stock outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options and restricted stock units into common stock using the treasury method unless the effect is antidilutive. The following table summarizes the calculation of basic and diluted net loss per share of common stock: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2024 2023 2024 2023 Net loss $ (4,802 ) $ (1,239 ) $ (12,423 ) $ (1,597 ) Weighted average shares outstanding - basic 43,614 42,688 43,499 42,345 Dilutive effect of equity awards - - - - Weighted average shares outstanding - diluted 43,614 42,688 43,499 42,345 Basic loss per share $ (0.11 ) $ (0.03 ) $ (0.29 ) $ (0.04 ) Diluted loss per share $ (0.11 ) $ (0.03 ) $ (0.29 ) $ (0.04 ) Shares excluded from diluted loss per share due to their anti-dilutive effect 3,988 3,952 3,730 3,847

Note 3 - Revenues

Note 3 - Revenues	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenues The following tables represent a disaggregation of revenues from contracts with customers for the three and nine months ended September 30, 2024 and 2023: Revenues by type were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Instruments, equipment, software and accessories $ 20,543 $ 23,500 $ 64,594 $ 79,261 Service, maintenance and warranty contracts 1,427 1,863 4,985 4,836 Total revenues $ 21,970 $ 25,363 $ 69,579 $ 84,097 Revenues by timing of recognition were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Goods and services transferred at a point in time $ 21,119 $ 24,668 $ 66,845 $ 81,610 Goods and services transferred over time 851 695 2,734 2,487 Total revenues $ 21,970 $ 25,363 $ 69,579 $ 84,097 Revenues by geographic destination were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 United States $ 9,706 $ 12,017 $ 31,495 $ 36,655 Europe 6,501 7,063 19,613 23,836 Greater China 2,731 3,489 10,426 13,824 Rest of the world 3,031 2,794 8,045 9,782 Total revenues $ 21,969 $ 25,363 $ 69,579 $ 84,097 Contract Liabilities The following table provides details of contract liabilities as of the periods indicated: (dollars in thousands) September 30, 2024 December 31, 2023 Change Percentage Service, maintenance and warranty contracts $ 2,472 $ 2,849 $ (377 ) -13.2 % Customer advances 1,217 1,659 (442 ) -26.6 % Total contract liabilities $ 3,689 $ 4,508 $ (819 ) -18.2 % Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service, maintenance and warranty contracts and lower sales volumes. During the three months ended September 30, 2024 and 2023, the Company recognized revenues of $0.4 million and $1.0 million from contract liabilities existing at December 31, 2023 and 2022, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized revenues of $3.0 million and $2.3 million from contract liabilities existing at December 31, 2023 and 2022, respectively. Provision for Expected Credit Losses on Receivables Activity in the provision for expected credit losses on receivables was as follows: Nine Months Ended September 30, (in thousands) 2024 2023 Balance, beginning of period $ 160 $ 191 Provision for expected credit losses 13 9 Charge-offs and other 1 (56 ) Balance, end of period $ 174 $ 144 Concentrations No customer accounted for more than 10% of revenues for the three and nine months ended September 30, 2024 and 2023. At September 30, 2024 and December 31, 2023, no customer accounted for more than 10% of net accounts receivable. Warranties Activity in the product warranties accrual was as follows: Nine Months Ended September 30, (in thousands) 2024 2023 Balance, beginning of period $ 336 $ 268 Provision for warranties 307 254 Warranty claims (228 ) (214 ) Balance, end of period $ 415 $ 308

Note 4 - Goodwill and Intangibl

Note 4 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. Goodwill and Intangible Assets The change in the carrying amount of goodwill for the nine months ended September 30, 2024 was as follows: (in thousands) Carrying amount at December 31, 2023 $ 57,065 Effect of change in currency translation 374 Carrying amount at September 30, 2024 $ 57,439 Intangible assets, net at September 30, 2024 and December 31, 2023 consisted of the following: September 30, 2024 December 31, 2023 (in thousands) Accumulated Accumulated Amortizable intangible assets: Gross Amortization Net Gross Amortization Net Customer relationships $ 16,026 $ (10,538 ) $ 5,488 $ 16,038 $ (9,706 ) $ 6,332 Technology and software development 35,468 (29,893 ) 5,575 35,007 (27,029 ) 7,978 Trade names and patents 7,606 (6,536 ) 1,070 7,613 (6,094 ) 1,519 Total amortizable intangible assets $ 59,100 $ (46,967 ) $ 12,133 $ 58,658 $ (42,829 ) $ 15,829 Indefinite-lived intangible assets: 208 207 Total intangible assets $ 12,341 $ 16,036 Intangible asset amortization expense for the three and nine months ended September 30, 2024 and 2023 was as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenues $ 44 $ - $ 131 $ - Operating expense 1,334 1,361 3,998 4,138 Total amortization of intangible assets $ 1,378 $ 1,361 $ 4,129 $ 4,138 As of September 30, 2024, estimated future amortization expense of amortizable intangible assets is as follows: (in thousands) 2024 (remainder of the year) $ 1,306 2025 4,201 2026 2,540 2027 1,269 2028 1,476 Thereafter 1,341 Total $ 12,133

Note 5 - Balance Sheet Informat

Note 5 - Balance Sheet Information	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	5. Balance Sheet Information The following tables provide details of selected balance sheet items as of the periods indicated: Inventories: September 30, December 31, (in thousands) 2024 2023 Finished goods $ 4,752 $ 5,120 Work in process 3,471 4,188 Raw materials 17,767 15,408 Total $ 25,990 $ 24,716 Other Current Liabilities: September 30, December 31, (in thousands) 2024 2023 Compensation $ 1,856 $ 3,929 Customer credits 1,123 3,201 Current portion of operating lease liabilities 1,127 1,416 Employee retention tax credit funds 3,154 - Professional fees 874 499 Warranty costs 415 336 Other 1,624 1,240 Total $ 10,173 $ 10,621 The Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”) provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company elected to account for the credit as a government grant. As there is no authoritative guidance under U.S. GAAP on accounting for grants to for-profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance The Company received ERTC refunds of $3.2 million during the nine months ended September 30, 2024. Due to the subjectivity of the credit, the Company has included the refunds received in other current liabilities in the consolidated balance sheet as of September 30, 2024, subject to a determination that the refunds are recognizable. The Company engaged a professional services firm under a commission fee arrangement to assist with determining the Company’s eligibility to claim the ERTC refunds and accumulating the necessary support that was used as a basis in the filing. During the nine months ended September 30, 2024, the Company paid fees of $0.5 million for these services, which are included in other operating expenses in the consolidated statement of operations.

Note 6 - Marketable Equity Secu

Note 6 - Marketable Equity Securities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	6. Marketable Equity Securities In April 2023, the Company received shares of common stock of Harvard Apparatus Regenerative Technology, Inc. (“HRGN”, formerly known as Biostage, Inc.) in connection with settlement of indemnification obligations related to litigation which was resolved during the year ended December 31, 2022. As of December 31, 2023, these shares had an estimated fair value $3.5 million and are included in the consolidated balance sheet as a component of other long-term assets. During the nine months ended September 30, 2024, the Company sold its HRGN shares for $1.9 million and recorded a loss on equity securities of $1.6 million. The Company recorded unrealized gains (losses) of $1.2 million and $(0.4) million during the three and nine months ended September 30, 2023, respectively.

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Leases The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030. The components of lease expense for the three and nine months ended September 30, 2024 and 2023, were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Operating lease cost $ 520 $ 491 $ 1,539 $ 1,517 Short-term lease cost 46 19 148 150 Sublease income (17 ) (25 ) (68 ) (76 ) Total lease cost $ 549 $ 485 $ 1,619 $ 1,591 Supplemental cash flow information related to the Company's operating leases is as follows: Nine Months Ended September 30, (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities $ 1,745 $ 1,764 Right-of-use assets obtained in exchange for lease obligations 2,945 277 Supplemental balance sheet information related to the Company’s operating leases is as follows: September 30, December 31, (in thousands) 2024 2023 Operating lease right-of-use assets $ 6,523 $ 4,773 Current portion, operating lease liabilities $ 1,127 $ 1,416 Operating lease liabilities, long-term 6,706 4,794 Total operating lease liabilities $ 7,833 $ 6,210 Weighted average remaining lease term (years) 5 Weighted average discount rate 8.9 % Future minimum lease payments for operating leases, with initial terms in excess of one year at September 30, 2024, are as follows: (in thousands) 2024 (remainder of the year) $ 425 2025 1,808 2026 1,812 2027 1,785 2028 1,774 Thereafter 2,408 Total lease payments 10,012 Less imputed interest (2,179 ) Total operating lease liabilities $ 7,833

Note 8 - Long-term Debt

Note 8 - Long-term Debt	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	8. Long-Term Debt As of September 30, 2024 and December 31, 2023, the Company’s long-term debt was as follows: (in thousands) September 30, 2024 December 31, 2023 Long-term debt: Term loan $ 25,700 $ 30,723 Revolving line 12,650 6,400 Less: unamortized deferred financing costs (492 ) (560 ) Total debt 37,858 36,563 Less: current portion of long-term debt (4,000 ) (6,139 ) Current unamortized deferred financing costs 394 280 Long-term debt $ 34,252 $ 30,704 The Company maintains a Credit Agreement (as amended, the “Credit Agreement”) with Citizens Bank, N.A., Wells Fargo Bank, National Association, and First Citizens Bank & Trust Company (together, the “Lenders”). The Credit Agreement provides for a term loan of $40.0 million and a $25.0 million revolving credit facility (including a $10.0 million sub-facility for the issuance of letters of credit and a $10.0 million swingline loan sub facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are secured by substantially all of the assets of Harvard Bioscience, Inc., including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries. The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly-owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Credit Facility. Issuance costs of $1.6 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Total revolver borrowing capacity is limited by the consolidated net leverage ratio as defined under the amended Credit Agreement. As of the date of this report, the Company is unable to make additional borrowings under its revolving credit facility and will be unable to make any such borrowings until it delivers to the lenders its financial statements for the year ending December 31, 2024, due to net leverage ratio requirements set forth in the August 6, 2024 amendment to the Credit Agreement (the “August 2024 Amendment”), as described below. Borrowings under the Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement (a “SOFR Loan”), subject to a floor of 0.50%, or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement (an “ABR Loan”). The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0%. Pursuant to the August 2024 Amendment, the applicable interest rate margin varies from 2.0% per annum to 3.75% per annum for SOFR Loans, and from 1.5% per annum to 3.5% per annum for ABR Loans, in each case depending on the Company’s consolidated net leverage ratio, and is determined in accordance with a pricing grid set forth in the Credit Agreement, as amended. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to SOFR Loan breakage and redeployment costs in certain circumstances. The effective interest rate on the Company’s borrowings for the three months ended September 30, 2024 and 2023, was 8.7% and 8.3%, respectively, and for the nine months ended September 30, 2024 and 2023, was 8.1% and 8.2%, respectively. The weighted average interest rate as of September 30, 2024, net of the effect of the Company’s interest rate swap agreement, was 8.6%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments. As of September 30, 2024, the term loan requires quarterly installment payments of $1.0 million with a balloon payment at maturity on December 22, 2025. Furthermore, within ninety days after the end of the Company’s fiscal year, the term loan may be permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep”, as defined in the Credit Agreement, provided that, in any fiscal year, any voluntary prepayments of the term loan shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. As of December 31, 2023, the current portion of long-term debt included amounts due under the excess cash flow sweep of $2.0 million which was paid on March 29, 2024. Amounts outstanding under the revolving credit facility can be repaid at any time but are due in full at maturity. The Credit Agreement includes various customary financial covenants and other affirmative and negative covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, permit liens, make investments, sell assets, or pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement also includes customary events of default. In March 2024, the Company entered into an amendment to the Credit Agreement pursuant to which the Lenders and administrative agent modified the definition of Consolidated EBITDA used in the calculation of certain financial covenants to adjust for charges related to an abandoned property audit (see Note 13) and commission fees in connection with ERTC filings (see Note 5). In August 2024, the Company entered into an amendment to the Credit Agreement that, among other things, modified the financial covenants relating to the consolidated net leverage ratio and consolidated fixed charge coverage ratio through the period ended December 31, 2024. The amendment also added a net leverage ratio requirement with respect to additional borrowing under the Company’s revolving credit facility and restrictions on certain additional indebtedness and investments, in each case until the Company delivers to the Lenders the Company’s financial statements for the fiscal year ending December 31, 2024. In addition, until delivery of such financial statements, the applicable interest rate margin is increased by 50bps during such time as the Company’s consolidated net leverage ratio is greater than 3.0. The Company paid fees of $0.2 million to the Lenders in connection with the amendment. As of September 30, 2024, the Company was in compliance with the financial covenants of the Credit Agreement. As of the date of this report, the Company is unable to make additional borrowings under its revolving credit facility and will be unable to make any such borrowings until it delivers to the lenders its financial statements for the year ending December 31, 2024, due to net leverage ratio requirements set forth in the August 2024 Amendment.

Note 9 - Derivatives

Note 9 - Derivatives	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	9. Derivatives In February 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract had a notional amount of $23.1 million as of September 30, 2024 and matures on December 22, 2025. This swap contract effectively converts the SOFR-based variable portion of the interest payable under the Credit Agreement into fixed-rate debt at an annual rate of 4.75%. The swap contract does not impact the additional interest related to the applicable interest rate margin as discussed above in Note 8, Long-Term Debt. The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of other comprehensive income (“OCI”) in the consolidated financial statements and are reclassified when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness. The following table presents the notional amount and fair value of the Company’s derivative instruments as of September 30, 2024 and December 31, 2023: (in thousands) September 30, 2024 December 31, 2023 Derivatives Instruments Balance Sheet Classification Notional Amount Fair Value (a) Notional Amount Fair Value (a) Interest rate swap Other long-term liabilities $ 23,062 $ (223 ) $ 27,375 $ (199 ) (a) See Note 10 for the fair value measurements related to these financial instruments. The effect of the cash flow hedge on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended Nine Months Ended Derivatives Qualifying as Hedges, net of tax September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 (Loss) gain recognized in OCI on derivatives (effective portion) $ (257 ) $ 117 $ (24 ) $ 126 Gain reclassified from accumulated OCI to interest expense 42 46 133 72

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	10. Fair Value Measurements The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis: Fair Value as of September 30, 2024 Assets (Liabilities) Level 1 Level 2 Level 3 Total Interest rate swap agreement $ - $ (223 ) $ - $ (223 ) Fair Value as of December 31, 2023 Level 1 Level 2 Level 3 Total Equity securities - common stock $ 3,511 $ - $ - $ 3,511 Interest rate swap agreement $ - $ (199 ) $ - $ (199 ) The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, investments in common stock and derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreement was based on SOFR yield curves at the reporting date. The fair value of the Company’s investment in HRGN common stock (see Note 6) was based on the closing price per the OTCQB Marketplace at the reporting date.

Note 11 - Stock-Based Compensat

Note 11 - Stock-Based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	11. Stock-Based Compensation Stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 was allocated as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenues $ (30 ) $ 58 $ 88 $ 222 Sales and marketing expenses 164 193 453 533 General and administrative expenses 795 1,012 2,493 2,585 Research and development expenses 124 100 345 278 Total stock-based compensation $ 1,053 $ 1,363 $ 3,379 $ 3,618 As of September 30, 2024, the total compensation costs related to unvested awards not yet recognized was $5.7 million and the weighted average period over which it is expected to be recognized is approximately 1.8 years. The Company did not capitalize any stock-based compensation. Restricted stock unit (“RSU”) activity for the nine months ended September 30, 2024 was as follows: Market- Performance- Time-Based Based Based Restricted Grant Date Restricted Grant Date Restricted Grant Date Stock Units Fair Value Stock Units Fair Value Stock Units Fair Value Balance at December 31, 2023 1,164,996 $ 3.28 801,845 $ 3.37 - $ - Granted 1,002,520 3.98 - - 375,895 4.19 Vested (150,383 ) 4.95 - - - - Forfeited (120,892 ) 3.64 - - - - Balance at September 30, 2024 1,896,241 $ 3.49 801,845 $ 3.37 375,895 $ 4.19 Unvested shares related to market-based and performance-based vesting conditions are reflected at 100% of their target vesting amount in the table above. Actual vesting could range from zero Performance-based RSU awards are contingent on the achievement of certain performance metrics. Compensation cost associated with performance-based RSUs are recognized based on the estimated number of shares that the Company ultimately expects will be earned. If the estimated number of shares to be earned is revised in the future, then stock-based compensation expense will be adjusted accordingly. Stock option activity for the nine months ended September 30, 2024 was as follows: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding and exercisable at December 31, 2023 924,067 $ 3.37 Exercised (13,586 ) 3.18 Cancelled/Forfeited (23,766 ) 4.54 Outstanding and exercisable at September 30, 2024 886,715 $ 3.34 2.7 $ 28 The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $2.69 as of the last trading day of the reporting period, which would have been received by the option holders had all option holders exercised their options as of that date. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024, was not

Note 12 - Income Tax

Note 12 - Income Tax	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Tax The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which the Company operates and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, the Company’s tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions. Income tax expense was $0.3 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and was $0.2 million and $0.1 million for the nine months ended September 30, 2024 and 2023, respectively. The Company’s effective tax rates of (6.9)% and (1.4)% for the three and nine months ended September 30, 2024, respectively, were different than the U.S. statutory rate primarily due to the inclusion of non-deductible executive compensation and changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets. The Company’s effective tax rates of (120.5)% and (9.9)% for the three and nine months ended September 30, 2023, respectively, were different than the U.S. statutory rate primarily due to the mix of forecasted income or losses in the U.S. and foreign tax jurisdictions and a Global Intangible Low-Taxed Income (“GILTI”) inclusion to taxable income. The effective tax rates in both the three and nine months ended September 30, 2023, were also impacted by changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingent Liabilities The Company is involved in various claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business, financial condition, results of operations or cash flows. Although unfavorable outcomes in the proceedings are possible, the Company has not accrued loss contingencies relating to any such matters as they are not considered to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company’s business, financial condition, results of operations and cash flows could be material. In addition, the Company has entered into indemnification agreements with its directors and officers. It is not possible to determine the maximum potential liability amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. The Company has not The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company recorded an expense of $0.3 million during the nine months ended September 30, 2024 related to unclaimed property audits which have been included in other operating expenses in the consolidated statement of operations.

Note 14 - Product Line Disposit

Note 14 - Product Line Disposition	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	14. Product Line Disposition In February 2023, the Company sold its Hoefer product line for $0.5 million. The carrying value of assets sold was $0.1 million resulting in a gain on disposition of $0.4 million which was recorded in other income (expense), net in the consolidated statement of operations for the nine months ended September 30, 2023. Revenues and gross profit of this disposed product line included in the condensed consolidated statement of operations for the nine months ended September 30, 2023 were not significant.

Note 15 - Restructuring and Oth

Note 15 - Restructuring and Other Exit Costs	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	15. Restructuring and Other Exit Costs On an ongoing basis, the Company reviews the global economy, the life sciences industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420, Exit or Disposal Cost Obligations During the nine months ended September 30, 2024, the Company completed restructurings and incurred expenses of $0.6 million, primarily consisting of severance incurred in connection with headcount reductions in Europe and North America. The changes in the accrued liability for restructuring and other charges for the nine months ended September 30, 2024 were as follows: (in thousands) Inventory-Related Severance Total Balance at December 31, 2023 $ 84 $ - $ 84 Restructuring and other exit costs 43 575 618 Non-cash charges (27 ) - (27 ) Cash payments (100 ) (470 ) (570 ) Balance at September 30, 2024 $ - $ 105 $ 105 The inventory-related costs are included in cost of revenues and the severance costs have been included as a component of other operating expenses (see Note 1).

Note 16 - Defined Benefit Plan

Note 16 - Defined Benefit Plan Settlement	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Defined Benefit Plan [Text Block]	16. Defined Benefit Plan Settlement During the three months ended September 30, 2024, the Company terminated its obligations under a defined benefit plan that was maintained by its subsidiary in the United Kingdom. This plan had been closed to new employees, as well as closed to the future accrual of benefits for existing employees since 2014 and represented approximately 11% percent of the Company's total pension liabilities as of December 31, 2023. The Company used $2.3 million of plan assets to purchase non-participating annuity contracts resulting in the full settlement of the benefit obligations. The Company recorded a non-cash charge of $1.2 million, including the immediate recognition of the portion of the accumulated OCI balances related to this plan. This charge has been presented as a component of other income (expense), net, for the three and nine months ended September 30, 2024.

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item 5. Other Information. None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Summary of Significant Accounting Policies The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2023 consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2024, results of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the anticipated operating results for the full year ending December 31, 2024, or any future periods. The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2024.
Liquidity, Policy [Policy Text Block]	Liquidity Primarily due to a decline in revenues, the Company experienced a net cash outflow from operations during the nine months ended September 30, 2024. The Company has substantial debt and other financial obligations. Any failure to meet these obligations or maintain compliance with the debt covenants contained in its credit agreement could have a material adverse effect on its business, financial condition and results of operations. As of the date of this report, the Company is unable to make additional borrowings under its revolving credit facility due to net leverage ratio requirements set forth in the Company’s credit agreement and will be unable to make any such borrowings until it delivers to the lenders its financial statements for the year ending December 31, 2024 (see note 8). The Company continues to take actions intended to improve liquidity, including actions related to cost containment and inventory reduction. Based on its current operating plans, the Company expects that its available cash and cash generated from operations will be sufficient to finance operations and capital expenditures and service its debt for at least the next 12 months. The Company’s ongoing cash flows and ability to meet its debt covenants are dependent on its revenues and operating performance. If the Company is unable to successfully carry out its operating plans or increase its revenues, its ability to maintain compliance with its debt covenants could be adversely affected.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables, and defined benefit pension obligations. Estimates are also required to assess the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company assesses its previous estimates based upon currently available information. Actual results could differ materially from those estimates.
Other Operating Expenses [Policy Text Block]	Other Operating Expenses The components of other operating expenses for the three and nine months ended September 30, 2024 were as follows: Three Months Ended Nine Months Ended (in thousands) September 30, 2024 September 30, 2024 Restructuring expenses (see Note 15) $ 179 $ 575 Unclaimed property audits expense (see Note 13) - 347 Employee retention credit fees (see Note 5) - 472 Total other operating expenses $ 179 $ 1,394
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Yet to Be Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) September 30, 2024 September 30, 2024 Restructuring expenses (see Note 15) $ 179 $ 575 Unclaimed property audits expense (see Note 13) - 347 Employee retention credit fees (see Note 5) - 472 Total other operating expenses $ 179 $ 1,394

Note 2 - Earnings (Loss) per _2

Note 2 - Earnings (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2024 2023 2024 2023 Net loss $ (4,802 ) $ (1,239 ) $ (12,423 ) $ (1,597 ) Weighted average shares outstanding - basic 43,614 42,688 43,499 42,345 Dilutive effect of equity awards - - - - Weighted average shares outstanding - diluted 43,614 42,688 43,499 42,345 Basic loss per share $ (0.11 ) $ (0.03 ) $ (0.29 ) $ (0.04 ) Diluted loss per share $ (0.11 ) $ (0.03 ) $ (0.29 ) $ (0.04 ) Shares excluded from diluted loss per share due to their anti-dilutive effect 3,988 3,952 3,730 3,847

Note 3 - Revenues (Tables)

Note 3 - Revenues (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Instruments, equipment, software and accessories $ 20,543 $ 23,500 $ 64,594 $ 79,261 Service, maintenance and warranty contracts 1,427 1,863 4,985 4,836 Total revenues $ 21,970 $ 25,363 $ 69,579 $ 84,097 Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Goods and services transferred at a point in time $ 21,119 $ 24,668 $ 66,845 $ 81,610 Goods and services transferred over time 851 695 2,734 2,487 Total revenues $ 21,970 $ 25,363 $ 69,579 $ 84,097
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 United States $ 9,706 $ 12,017 $ 31,495 $ 36,655 Europe 6,501 7,063 19,613 23,836 Greater China 2,731 3,489 10,426 13,824 Rest of the world 3,031 2,794 8,045 9,782 Total revenues $ 21,969 $ 25,363 $ 69,579 $ 84,097
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	(dollars in thousands) September 30, 2024 December 31, 2023 Change Percentage Service, maintenance and warranty contracts $ 2,472 $ 2,849 $ (377 ) -13.2 % Customer advances 1,217 1,659 (442 ) -26.6 % Total contract liabilities $ 3,689 $ 4,508 $ (819 ) -18.2 %
Financing Receivable, Allowance for Credit Loss [Table Text Block]	Nine Months Ended September 30, (in thousands) 2024 2023 Balance, beginning of period $ 160 $ 191 Provision for expected credit losses 13 9 Charge-offs and other 1 (56 ) Balance, end of period $ 174 $ 144
Schedule of Product Warranty Liability [Table Text Block]	Nine Months Ended September 30, (in thousands) 2024 2023 Balance, beginning of period $ 336 $ 268 Provision for warranties 307 254 Warranty claims (228 ) (214 ) Balance, end of period $ 415 $ 308

Note 4 - Goodwill and Intangi_2

Note 4 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	(in thousands) Carrying amount at December 31, 2023 $ 57,065 Effect of change in currency translation 374 Carrying amount at September 30, 2024 $ 57,439
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, 2024 December 31, 2023 (in thousands) Accumulated Accumulated Amortizable intangible assets: Gross Amortization Net Gross Amortization Net Customer relationships $ 16,026 $ (10,538 ) $ 5,488 $ 16,038 $ (9,706 ) $ 6,332 Technology and software development 35,468 (29,893 ) 5,575 35,007 (27,029 ) 7,978 Trade names and patents 7,606 (6,536 ) 1,070 7,613 (6,094 ) 1,519 Total amortizable intangible assets $ 59,100 $ (46,967 ) $ 12,133 $ 58,658 $ (42,829 ) $ 15,829 Indefinite-lived intangible assets: 208 207 Total intangible assets $ 12,341 $ 16,036
Finite-Lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenues $ 44 $ - $ 131 $ - Operating expense 1,334 1,361 3,998 4,138 Total amortization of intangible assets $ 1,378 $ 1,361 $ 4,129 $ 4,138
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(in thousands) 2024 (remainder of the year) $ 1,306 2025 4,201 2026 2,540 2027 1,269 2028 1,476 Thereafter 1,341 Total $ 12,133

Note 5 - Balance Sheet Inform_2

Note 5 - Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Inventories: September 30, December 31, (in thousands) 2024 2023 Finished goods $ 4,752 $ 5,120 Work in process 3,471 4,188 Raw materials 17,767 15,408 Total $ 25,990 $ 24,716
Other Current Liabilities [Table Text Block]	Other Current Liabilities: September 30, December 31, (in thousands) 2024 2023 Compensation $ 1,856 $ 3,929 Customer credits 1,123 3,201 Current portion of operating lease liabilities 1,127 1,416 Employee retention tax credit funds 3,154 - Professional fees 874 499 Warranty costs 415 336 Other 1,624 1,240 Total $ 10,173 $ 10,621

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Operating lease cost $ 520 $ 491 $ 1,539 $ 1,517 Short-term lease cost 46 19 148 150 Sublease income (17 ) (25 ) (68 ) (76 ) Total lease cost $ 549 $ 485 $ 1,619 $ 1,591
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]	Nine Months Ended September 30, (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities $ 1,745 $ 1,764 Right-of-use assets obtained in exchange for lease obligations 2,945 277
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]	September 30, December 31, (in thousands) 2024 2023 Operating lease right-of-use assets $ 6,523 $ 4,773 Current portion, operating lease liabilities $ 1,127 $ 1,416 Operating lease liabilities, long-term 6,706 4,794 Total operating lease liabilities $ 7,833 $ 6,210 Weighted average remaining lease term (years) 5 Weighted average discount rate 8.9 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	(in thousands) 2024 (remainder of the year) $ 425 2025 1,808 2026 1,812 2027 1,785 2028 1,774 Thereafter 2,408 Total lease payments 10,012 Less imputed interest (2,179 ) Total operating lease liabilities $ 7,833

Note 8 - Long-term Debt (Tables

Note 8 - Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	(in thousands) September 30, 2024 December 31, 2023 Long-term debt: Term loan $ 25,700 $ 30,723 Revolving line 12,650 6,400 Less: unamortized deferred financing costs (492 ) (560 ) Total debt 37,858 36,563 Less: current portion of long-term debt (4,000 ) (6,139 ) Current unamortized deferred financing costs 394 280 Long-term debt $ 34,252 $ 30,704

Note 9 - Derivatives (Tables)

Note 9 - Derivatives (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	(in thousands) September 30, 2024 December 31, 2023 Derivatives Instruments Balance Sheet Classification Notional Amount Fair Value (a) Notional Amount Fair Value (a) Interest rate swap Other long-term liabilities $ 23,062 $ (223 ) $ 27,375 $ (199 )
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Three Months Ended Nine Months Ended Derivatives Qualifying as Hedges, net of tax September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 (Loss) gain recognized in OCI on derivatives (effective portion) $ (257 ) $ 117 $ (24 ) $ 126 Gain reclassified from accumulated OCI to interest expense 42 46 133 72

Note 10 - Fair Value Measurem_2

Note 10 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value as of September 30, 2024 Assets (Liabilities) Level 1 Level 2 Level 3 Total Interest rate swap agreement $ - $ (223 ) $ - $ (223 ) Fair Value as of December 31, 2023 Level 1 Level 2 Level 3 Total Equity securities - common stock $ 3,511 $ - $ - $ 3,511 Interest rate swap agreement $ - $ (199 ) $ - $ (199 )

Note 11 - Stock-Based Compens_2

Note 11 - Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Cost of revenues $ (30 ) $ 58 $ 88 $ 222 Sales and marketing expenses 164 193 453 533 General and administrative expenses 795 1,012 2,493 2,585 Research and development expenses 124 100 345 278 Total stock-based compensation $ 1,053 $ 1,363 $ 3,379 $ 3,618
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Market- Performance- Time-Based Based Based Restricted Grant Date Restricted Grant Date Restricted Grant Date Stock Units Fair Value Stock Units Fair Value Stock Units Fair Value Balance at December 31, 2023 1,164,996 $ 3.28 801,845 $ 3.37 - $ - Granted 1,002,520 3.98 - - 375,895 4.19 Vested (150,383 ) 4.95 - - - - Forfeited (120,892 ) 3.64 - - - - Balance at September 30, 2024 1,896,241 $ 3.49 801,845 $ 3.37 375,895 $ 4.19
Schedule of Stock Options Roll Forward [Table Text Block]	Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding and exercisable at December 31, 2023 924,067 $ 3.37 Exercised (13,586 ) 3.18 Cancelled/Forfeited (23,766 ) 4.54 Outstanding and exercisable at September 30, 2024 886,715 $ 3.34 2.7 $ 28

Note 15 - Restructuring and O_2

Note 15 - Restructuring and Other Exit Costs (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Restructuring and Related Costs [Table Text Block]	(in thousands) Inventory-Related Severance Total Balance at December 31, 2023 $ 84 $ - $ 84 Restructuring and other exit costs 43 575 618 Non-cash charges (27 ) - (27 ) Cash payments (100 ) (470 ) (570 ) Balance at September 30, 2024 $ - $ 105 $ 105

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Other Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring expenses (see Note 15)	$ 179		$ 575
Unclaimed property audits expense (see Note 13)	0		347
Unclaimed property audits expense (see Note 13)	0		347
Employee retention credit fees (see Note 5)	0		472
Employee retention credit fees (see Note 5)	0		472
Total other operating expenses	$ 179	$ 0	$ 1,394	$ 0

Note 2 - Earnings (Loss) per _3

Note 2 - Earnings (Loss) per Share - Schedule of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net loss	$ (4,802)	$ (1,239)	$ (12,423)	$ (1,597)
Weighted average shares outstanding - basic (in shares)	43,614	42,688	43,499	42,345
Dilutive effect of equity awards (in shares)	0	0	0	0
Weighted average shares outstanding - diluted (in shares)	43,614	42,688	43,499	42,345
Basic (loss) income per share (in dollars per share)	$ (0.11)	$ (0.03)	$ (0.29)	$ (0.04)
Diluted (loss) income per share (in dollars per share)	$ (0.11)	$ (0.03)	$ (0.29)	$ (0.04)
due to their anti-dilutive effect (in shares)	3,988	3,952	3,730	3,847

Note 3 - Revenues (Details Text

Note 3 - Revenues (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Contract with Customer, Liability, Revenue Recognized	$ 0.4	$ 1	$ 3	$ 2.3

Note 3 - Revenues - Disaggregat

Note 3 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 21,969	$ 25,363	$ 69,579	$ 84,097
Transferred at Point in Time [Member]
Revenues	21,119	24,668	66,845	81,610
Transferred over Time [Member]
Revenues	851	695	2,734	2,487
Instruments, Equipment, Software, and Accessories [Member]
Revenues	20,543	23,500	64,594	79,261
Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 1,427	$ 1,863	$ 4,985	$ 4,836

Note 3 - Revenues - Revenue by

Note 3 - Revenues - Revenue by Geographic Destination (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenues	$ 21,969	$ 25,363	$ 69,579	$ 84,097
UNITED STATES
Total revenues	9,706	12,017	31,495	36,655
Europe [Member]
Total revenues	6,501	7,063	19,613	23,836
Greater China [Member]
Total revenues	2,731	3,489	10,426	13,824
Rest of the World [Member]
Total revenues	$ 3,031	$ 2,794	$ 8,045	$ 9,782

Note 3 - Revenues - Deferred Re

Note 3 - Revenues - Deferred Revenue (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Deferred revenue	$ 3,689		$ 4,508
Deferred Revenue, change	$ (819)	$ 635
Deferred revenue, % change	(18.20%)
Service, Maintenance, and Warranty Contracts [Member]
Deferred revenue	$ 2,472		2,849
Deferred Revenue, change	$ (377)
Deferred revenue, % change	(13.20%)
Customer Advances [Member]
Deferred revenue	$ 1,217		$ 1,659
Deferred Revenue, change	$ (442)
Deferred revenue, % change	(26.60%)

Note 3 - Revenues - Allowance f

Note 3 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2024
Balance, beginning of period	$ 191	$ 160
Provision for expected credit losses	9	13
Charge-offs and other	(56)	1
Balance, end of period	$ 144	$ 174

Note 3 - Revenues - Warranties

Note 3 - Revenues - Warranties (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Balance	$ 336	$ 268
Provision for warranties	307	254
Warranty claims	(228)	(214)
Balance	$ 415	$ 308

Note 4 - Goodwill and Intangi_3

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Carrying amount	$ 57,065
Effect of change in currency translation	374
Carrying amount	$ 57,439

Note 4 - Goodwill and Intangi_4

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets, Gross	$ 59,100	$ 58,658
Total amortizable intangible assets	(46,967)	(42,829)
Finite-Lived Intangible Assets, Net	12,133	15,829
Indefinite-lived intangible assets:	208	207
Intangible assets, net	12,341	16,036
Distribution Agreements/Customer Relationships [Member]
Finite-Lived Intangible Assets, Gross	16,026	16,038
Total amortizable intangible assets	(10,538)	(9,706)
Finite-Lived Intangible Assets, Net	5,488	6,332
Existing Technology and Software Development [Member]
Finite-Lived Intangible Assets, Gross	35,468	35,007
Total amortizable intangible assets	(29,893)	(27,029)
Finite-Lived Intangible Assets, Net	5,575	7,978
Trade Names and Patents [Member]
Finite-Lived Intangible Assets, Gross	7,606	7,613
Total amortizable intangible assets	(6,536)	(6,094)
Finite-Lived Intangible Assets, Net	$ 1,070	$ 1,519

Note 4 - Goodwill and Intangi_5

Note 4 - Goodwill and Intangible Assets - Schedule of Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total amortization of intangible assets	$ 1,378	$ 1,361	$ 4,129	$ 4,138
Cost of Revenues [Member]
Total amortization of intangible assets	44	0	131	0
Operating Expense [Member]
Total amortization of intangible assets	$ 1,334	$ 1,361	$ 3,998	$ 4,138

Note 4 - Goodwill and Intangi_6

Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
2024 (remainder of the year)	$ 1,306
2025	4,201
2026	2,540
2027	1,269
2028	1,476
Thereafter	1,341
Total	$ 12,133	$ 15,829

Note 5 - Balance Sheet Inform_3

Note 5 - Balance Sheet Information (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Proceeds from Employee Retention Credit Refund		$ 3,200
Employee retention credit fees (see Note 5)	$ 0	$ 472

Note 5 - Balance Sheet Inform_4

Note 5 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finished goods	$ 4,752	$ 5,120
Work in process	3,471	4,188
Raw materials	17,767	15,408
Total	$ 25,990	$ 24,716

Note 5 - Balance Sheet Inform_5

Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Compensation	$ 1,856	$ 3,929
Customer credits	1,123	3,201
Current portion of operating lease liabilities	1,127	1,416
Employee retention credit funds	3,154	0
Professional fees	874	499
Warranty costs	415	336
Other	1,624	1,240
Total	$ 10,173	$ 10,621

Note 6 - Marketable Equity Se_2

Note 6 - Marketable Equity Securities (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Proceeds from Sale of Equity Securities, FV-NI		$ 1,919	$ 0
Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member]
Investment Owned, Fair Value				$ 3,500
Proceeds from Sale of Equity Securities, FV-NI		1,900
Equity Securities, FV-NI, Realized Loss		1,600
Equity Securities, FV-NI, Unrealized Loss	$ 1,200	$ 400

Note 7 - Leases - Lease Expense

Note 7 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating lease cost	$ 520	$ 491	$ 1,539	$ 1,517
Short-term lease cost	46	19	148	150
Sublease income	(17)	(25)	(68)	(76)
Total lease cost	$ 549	$ 485	$ 1,619	$ 1,591

Note 7 - Leases - Supplemental

Note 7 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities	$ 1,745	$ 1,764
Right-of-use assets obtained in exchange for lease obligations	$ 2,945	$ 277

Note 7 - Leases - Supplementa_2

Note 7 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Operating lease right-of-use assets	$ 6,523	$ 4,773
Current portion, operating lease liabilities	1,127	1,416
Operating lease liabilities, long-term	6,706	4,794
Total operating lease liabilities	$ 7,833	$ 6,210
Weighted average remaining lease term (years) (Year)	5 years
Weighted average discount rate	8.90%

Note 7 - Leases - Future Minimu

Note 7 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
2024 (remainder of the year)	$ 425
2025	1,808
2026	1,812
2027	1,785
2028	1,774
Thereafter	2,408
Total lease payments	10,012
Less imputed interest	(2,179)
Total operating lease liabilities	$ 7,833	$ 6,210

Note 8 - Long-term Debt (Detail

Note 8 - Long-term Debt (Details Textual) - USD ($) $ in Thousands	3 Months Ended		5 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Aug. 01, 2024	Mar. 29, 2024	Dec. 31, 2023	Dec. 22, 2020
Debt Issuance Costs, Net, Total	$ 492			$ 492				$ 560
Line of Credit Facility, Interest Rate at Period End	8.60%			8.60%
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total									$ 1,600
Line of Credit Facility, Interest Rate During Period	8.70%	8.30%		8.10%	8.20%
Debt Instrument, Quarterly Payment, Thereafter	$ 1,000			$ 1,000
Debt Instrument, Current Maturities, Excess Cash Flow Sweep							$ 2,000
Debt Instrument, Fee Amount						$ 200
The Credit Agreement [Member] | Forecast [Member]
Debt Instrument, Basis Spread on Variable Rate, Increase (Decrease)			5,000%
The Credit Agreement [Member] | Minimum [Member] | Forecast [Member]
Debt Instrument, Net Leverage Ratio			3
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage	0.50%			0.50%
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate				3.75%
The Credit Agreement [Member] | Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage	1%			1%
The Credit Agreement [Member] | The ABR Loan [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate				1.50%
The Credit Agreement [Member] | The ABR Loan [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate				3.50%
Term Loan [Member]
Long-Term Debt, Gross	$ 25,700			$ 25,700				$ 30,723
The SOFR Loan and Pricing Grid Credit Agreement [Member] | The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate				2%
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity									25,000
The Lenders [Member] | The Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity									10,000
The Lenders [Member] | The Credit Agreement [Member] | Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity									10,000
The Lenders [Member] | Term Loan [Member] | The Credit Agreement [Member]
Long-Term Debt, Gross									$ 40,000

Note 8 - Long-term Debt - Break

Note 8 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Less: unamortized deferred financing costs	$ (492)	$ (560)
Total debt	37,858	36,563
Less: current portion of long-term debt	(4,000)	(6,139)
Current unamortized deferred financing costs	394	280
Long-term debt	34,252	30,704
Term Loan [Member]
Long-term debt, gross	25,700	30,723
Line of Credit [Member]
Long-term debt, gross	$ 12,650	$ 6,400

Note 9 - Derivatives (Details T

Note 9 - Derivatives (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Derivative, Notional Amount	$ 23,062	$ 27,375
The Credit Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Interest Rate Swap [Member]
Derivative, Notional Amount	$ 23,100

Note 9 - Derivatives - Derivati

Note 9 - Derivatives - Derivative Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Interest rate swap, notional	$ 23,062	$ 27,375
Derivative, Fair Value, Net	$ 223	$ (199)

Note 9 - Derivatives - The Effe

Note 9 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Gain (loss) recognized in OCI on derivatives (effective portion)	$ (257)	$ 117	$ (24)	$ 126
Gian (loss) reclassified from OCI to interest expense	$ 42	$ 46	$ 133	$ 72

Note 10 - Fair Value Measurem_3

Note 10 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Equity securities - common stock		$ 3,511
Fair Value, Inputs, Level 1 [Member]
Equity securities - common stock		3,511
Fair Value, Inputs, Level 2 [Member]
Equity securities - common stock		0
Fair Value, Inputs, Level 3 [Member]
Equity securities - common stock		0
Interest Rate Swap [Member]
Derivative liabilities	$ (223)	(199)
Interest Rate Swap [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liabilities	0	0
Interest Rate Swap [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liabilities	(223)	(199)
Interest Rate Swap [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 0	$ 0

Note 11 - Stock-Based Compens_3

Note 11 - Stock-Based Compensation (Details Textual) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 5,700
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 9 months 18 days
Vesting Rate of the Targeted Shareholder Return	100%
Minimum Vesting Rate of the Targeted Shareholder Return, Percentage	0%
Maximum Vesting Rate of the Targeted Shareholder Return, Percentage	150%
Share Price | $ / shares	$ 2.69
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 0

Note 11 - Stock-Based Compens_4

Note 11 - Stock-Based Compensation - Stock-based Compensation Expense (Details) - Continuing Operations [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based compensation	$ 1,053	$ 1,363	$ 3,379	$ 3,618
Cost of Sales [Member]
Share-based compensation	(30)	58	88	222
Selling and Marketing Expense [Member]
Share-based compensation	164	193	453	533
General and Administrative Expense [Member]
Share-based compensation	795	1,012	2,493	2,585
Research and Development Expense [Member]
Share-based compensation	$ 124	$ 100	$ 345	$ 278

Note 11 - Stock-Based Compens_5

Note 11 - Stock-Based Compensation - Activity of Restricted Stock Units (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Time-based Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) | shares	1,164,996
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.28
Restricted Stock Units, Granted in Period (in shares) | shares	1,002,520
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.98
Restricted Stock Units, Vested in Period (in shares) | shares	(150,383)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 4.95
Restricted Stock Units, Forfeited in Period (in shares) | shares	(120,892)
Restricted Stock Units, Forfeited, Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.64
Restricted Stock Units Outstanding , Balance (in shares) | shares	1,896,241
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.49
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) | shares	801,845
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.37
Restricted Stock Units, Granted in Period (in shares) | shares	0
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units, Vested in Period (in shares) | shares	0
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units, Forfeited in Period (in shares) | shares	0
Restricted Stock Units, Forfeited, Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units Outstanding , Balance (in shares) | shares	801,845
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.37
Performance-based Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) | shares	0
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units, Granted in Period (in shares) | shares	375,895
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 4.19
Restricted Stock Units, Vested in Period (in shares) | shares	0
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units, Forfeited in Period (in shares) | shares	0
Restricted Stock Units, Forfeited, Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 0
Restricted Stock Units Outstanding , Balance (in shares) | shares	375,895
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 4.19

Note 11 - Stock-Based Compens_6

Note 11 - Stock-Based Compensation - Stock-Based Payment Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024
Outstanding and Exerciseable, shares (in shares)	924,067
Outstanding and Exerciseable, weighted average exercise price (in dollars per share)	$ 3.37
Exercised, shares (in shares)	(13,586)
Exercised, weighted average exercise price (in dollars per share)	$ 3.18
Cancelled/Forfeited (in shares)	23,766
Cancelled/Forfeited (in dollars per share)	$ 4.54
Outstanding and Exerciseable, shares (in shares)	886,715
Outstanding and Exerciseable, weighted average exercise price (in dollars per share)	$ 3.34
Outstanding and Exerciseable, contractual term (Year)	3 years 2 months 12 days
Outstanding and Exerciseable, aggregated intrinsic value	$ 28

Note 12 - Income Tax (Details T

Note 12 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Expense (Benefit)	$ 311	$ 677	$ 168	$ 144
Income tax expense	$ 311	$ 677	$ 168	$ 144
Effective Income Tax Rate Reconciliation, Percent	6.90%	120.50%	1.40%	9.90%

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingent Liabilities (Details Textual) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)
Unclaimed property audits expense (see Note 13)	$ 0	$ 347
Director [Member] | Indemnification Agreements [Member]
Liability for Contingent Indemnification Obligations	$ 0	$ 0

Note 14 - Product Line Dispos_2

Note 14 - Product Line Disposition (Details Textual) - USD ($) $ in Thousands		9 Months Ended
	Feb. 17, 2023	Sep. 30, 2024	Sep. 30, 2023
Gain (Loss) on Disposition of Business		$ 0	$ 403
Hoefer Product Line [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 500
Disposal Group, Including Discontinued Operation, Assets	100
Gain (Loss) on Disposition of Business	$ 400

Note 15 - Restructuring and O_3

Note 15 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Restructuring Charges	$ 179	$ 575
Employee Severance [Member] | Europe and North America [Member]
Restructuring Charges		$ 600

Note 15 - Restructuring and O_4

Note 15 - Restructuring and Other Exit Costs - Restructuring and Related Costs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Balance at December 31, 2023	$ 84
Restructuring and other exit costs	618
Non-cash charges	(27)
Cash payments	(570)
Balance at September 30, 2024	105
Cost of Revenues [Member]
Balance at December 31, 2023	84
Restructuring and other exit costs	43
Non-cash charges	(27)
Cash payments	(100)
Balance at September 30, 2024	0
Employee Severance [Member]
Balance at December 31, 2023	0
Restructuring and other exit costs	575
Non-cash charges	0
Cash payments	(470)
Balance at September 30, 2024	$ 105

Note 16 - Defined Benefit Pla_2

Note 16 - Defined Benefit Plan Settlement (Details Textual) $ in Millions	3 Months Ended
	Sep. 30, 2024 USD ($)
Percentage Of Liability, Defined Benefit Plan	11%
Assets for Plan Benefits, Defined Benefit Plan	$ 2.3
Defined Benefit Plan, Plan Assets, Amount	$ 1.2